......... 25 7.4.3. Final Analysis and Publication of Study Results ................................ .......................... 25 OSE Immunotherapeutics v2.2 Study OSE2101C301 (ATALANTE 1) Statistical Analysis Plan 2021 -07-23 IND#: BB-IND 10802 CONFIDENTIAL P a g e | 4/51 8. SUMMARY OF STUDY DATA ................................